Pharm Aid Ltd. is set to become the leading
vaccine facility in Russia that offers full-cycle technology.

We are building the country’s first live virus manufacturing line and a range of products developed both in-house and alongside our international partners, focusing on innovative combined immunobiological drugs for the prevention and treatment of significant diseases.

Within our bespoke, high-tech facility, our R&D department combines the best practices available from Russian and global companies in biotechnologies development in order to increase the accessibility of quality treatments to Russian patients.



We seek to provide affordable and high-quality healthcare to all via a modern, full-cycle production facility with in-house R&D.

This is created thanks to international partnership with a leading pharmaceutical company, enabling vaccine technology transfer, manufacturing, & commercialisation.









Modern full-cycle production facility with in-house R&D created through international partnership with a leading pharmaceutical company enabling vaccine technology transfer, manufacturing, and commercialization

Pharm Aid  Ltd. was established on May 26, 2017, as a joint venture between Rostec State Corporation and Ishvan Pharmaceuticals Ltd. Its three key objectives are:

1. Transfer of technologies
2. Localized production of innovative combined
immunobiological drugs in Russia
3. Increased availability of effective therapy
for Russian patients.

The creation of the company is part of the Russian Federation’s strategy to achieve independence from the import of essential drugs. Achieving this will ensure sustainable development and modernisation of the national pharmaceutical industry, with the goal of producing new, low-priced drugs domestically and obtaining significant financial savings for the Federal healthcare budget.


Our primary area of focus is on the introduction of new vaccine production technologies for the Russian Federation. We are leading the way in this field, including cutting-edge mRNA technologies.

Our goal is to create a unique, world-class R&D centre on the PharmAid platform, along with sufficient manufacturing capabilities to create original, domestic immunobiological drugs.


We aim to create a complete manufacturing process cycle in the Russian Federation for the following vaccines and immunobiological preparations:

  • Varicella Vaccine
  • Rotavirus Vaccine
  • Human Papillomavirus Vaccine
  • Meningococcal Vaccine
  • Monoclonal Antibody for Rabies
  • MMR Vaccine (Measles, Mumps, Rubella)

Our full website will be launched soon. In the meantime, if you would like more information or would like to speak to us about specific areas of cooperation, then please fill in the form below and one of our senior managers will contact you directly.